Research Focus
The Trau Group, led by Senior Group Leader Professor Matt Trau, is dedicated to developing improved point-of-care diagnostics from the benchtop to bedside, with the goal of significantly enhancing patient outcomes and helping to transition the medical system towards early disease detection and personalised treatment. By understanding disease epigenetics and combining chemistry with nanotechnology, the Group’s research aims to provide improved accuracy over existing diagnostic devices, at a cheaper price.
Professor Trau has a joint appointment with SCMB.
